CM has received honoraria for lectures and/or advisory work from Novo Nordisk, sanofi-aventis, MSD, Eli Lilly, Novartis, BMS, AstraZeneca, Pfizer, J&J, and Mankind; her institution has received research support from Novo Nordisk, sanofi-avenis, MSD, Eli Lilly and Novartis. AHB has received honoraria for lectures and advisory work from Novartis, MSD, Boehinger-Ingleheim, Janssen Cilag, BMS/Astra-Zeneca, Novo Nordisk, Eli Lilly, Roche and sanofi-aventis. HB has received honoraria for lectures and advisory boards from all major diabetes companies, including Novartis, but has no specific conflict of interest relevant to the study. JJdC has received honoraria for advisory boards, consultancies and speakers bureaus from Bial, Bayer, BMS-Astra Zeneca, Boehringer-Ingelheim, Eli Lilly, Merck-Serono, Novartis, Novo Nordisk, and Recordati. IC has received honoraria and consulting fees as a member of scientific advisory board from Medtronic, Bayer, GSK, Eli Lilly, Novo Nordisk, sanofi-aventis, MSD and Novartis. RG has received honoraria for lectures. PMN has received honoraria for advisory boards and lectures from Novartis. AP has been on advisory boards for Novartis, Novo Nordisk, and sanofi-aventis has received compensation for development of educational materials from Abbott, Astra-Zeneca, BMS, J&J, MSD, Novartis, sanofi-aventis, Lilly and Boehringer-Ingelheim. He has travelled for and received expense reimbursement by MSD and sanofi-aventis. NCS and SKW declare no conflicts of interest. WK is an employee and shareholder of Novartis. GB is an employee of Novartis.